Company intelligence
Calidi Biotherapeutics
Pioneering systemic delivery of targeted oncolytic virotherapy through the RedTail platform. NYSEAMERICAN: CLDI
About Calidi Biotherapeutics
Calidi Biotherapeutics is developing a new modality in cancer treatment through its proprietary RedTail platform, designed for systemic delivery of modified oncolytic viruses with genetic payloads activated at the tumor site. Focused on patients with limited treatment options, the company is advancing therapies aimed at improving targeting, activity, and durability in solid tumors. Calidi continues to generate data and present at leading scientific meetings as it progresses toward early clinical data.
Verified activity
Signals from Calidi Biotherapeutics
4 published signals
Presence & Recognition
Calidi Biotherapeutics participated in the H.C. Wainwright & Co., LLC 28th Annual Global Investment Conference.
Reported by Calidi Biotherapeutics
Research & Knowledge
Calidi Biotherapeutics CEO Eric Poma, Ph.D., shared his perspective on targeted immune activation, drug delivery, and tumor microenvironment therapeutic activity in a new article published in Morgan Kohler's Drug Discovery Online.
Reported by Calidi Biotherapeutics
Products & Services
Calidi Biotherapeutics is exploring targeted immune activation through CLD-401 and its systemic oncolytic virotherapy platform.
Reported by Calidi Biotherapeutics
Presence & Recognition
Calidi Biotherapeutics CEO Eric Poma, Ph.D., shared insights into the future of systemically delivered oncolytic virotherapy in a recent Xtalks feature.
Reported by Calidi Biotherapeutics